BCL2 interacting protein 3 pseudogene 23Genealiases: []
Q-omics provides the consensus-scored BNIP3P23 profile across patient tissues and cancer cell-line models. BNIP3P23 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, BNIP3P23 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, BNIP3P23 RNA expression shows 9,088 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight OV, KIRC, and LIHC as cancer lineages where BNIP3P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P23 survival associations across molecular data types. BNIP3P23 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P23 RNA expression–survival associations across cancer types. High BNIP3P23 expression shows unfavorable associations in SARC, STAD, TGCT, UCEC and LIHC, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for BNIP3P23 RNA expression.
This table summarizes BNIP3P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P23 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher BNIP3P23 RNA expression in tumor versus normal tissue (log2 FC = +0.119, t-test p < 0.001).
This table shows molecular features associated with BNIP3P23 in patient tissues and cancer cell lines. In patient samples, BNIP3P23 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
